International Cannabis Weekly: 460

‘EVERYTHING IN OUR POWER’: GERMAN PATIENT GROUPS FIGHT TO OVERTURN CANNABIS INSURANCE CUTS

Earlier this month (July 10, 2026), the German government voted through a sweeping set of provisions set to significantly impact medical cannabis patients who have their prescriptions covered by their statutory health insurance.

READ MORE  »

CANNABIS FLAVONOID STOPS UP TO 99% OF CANCER CELL GROWTH DURING LAB TESTING

READ MORE »

CANNABIS GIANT SNDL CLAIMS TO BE WORLD’S LARGEST AFTER PARALLEL TAKEOVER

READ MORE »

• Cannabis use among German teenagers remains stable after legalisation as the medical market continues expansion.
• Cantourage strengthens its own-brand strategy to protect cannabis flower margins amid rising competition.
• European Union unveils cannabis toolkit designed to measure the real-world impact of legalisation.
• Medical cannabis programme linked to one-third reduction in drug arrests across Jersey.
• New Labour administration has the opportunity to end Britain’s failed cannabis policy experiment.
• German study reveals rising THC potency alongside falling cannabis prices across the market.
• France has introduced a new decree to further develop its medical cannabis framework.
• Under the Canary sun: first medical cannabis farm aims to transform the region into a pharmaceutical hub.
• EU cannabis toolkit: How Brussels wants to make the effect of legalisation measurable.

LEARN MORE »

• Cannabis flavonoid stops up to 99% of cancer cell growth during laboratory testing.
• Wisconsin governor urges Congress to preserve legal access to hemp-derived THC products.
• Rhode Island to refund cannabis business licence application fees after legal challenge.
• New Vermont law doubles legal cannabis possession limit to weaken the illicit market.
• Vireo Growth agrees all-stock acquisition deal to purchase multistate operator Planet 13.
• Utah medical cannabis company loses bid to block union effort using federal prohibition.
• San Francisco mayor clears the way for cannabis cafés serving food and soft drinks.
• New study explores how cannabis use is affecting performance and recovery among athletes.
• The hemp and cannabis industries are all vying for Trump’s attention.

• Tilray Brands reports record fiscal 2026 revenue alongside strong adjusted EBITDA growth.
• Aurora Cannabis announces timing for its first-quarter 2027 financial results presentation.
• Illegal diversion of Canadian cannabis into European markets is becoming a growing concern.
• Safari Flower secures EU-GMP certification for its Ontario cannabis production facility.
• Israel halts anti-dumping investigation into Canadian cannabis imports following procedural error.
• Veterans Affairs Canada introduces changes affecting medical cannabis reimbursement for veterans.
• Canadian recreational cannabis sales have climbed to CA$485 million during May 2026.
• Aurora’s Safari Flower company receives renewed EU-GMP certification at Niagara facility.

• Brazilian medical council releases new guidance on the use of medicinal cannabis treatments.
• Argentine university to host open event exploring cannabis science, policy and human rights.
• Panamanian pharmacies face tougher compliance rules for dispensing medical cannabis products. 

• MediGrowth partners with Chronic Pain Australia to answer patients’ biggest cannabis questions.
• Vitura’s new chief executive says Australia’s cannabis industry must mature for future success.
• South Korea invests US$21 million into minor cannabinoid research for medical hemp products.
• The Cannabis Licensing Authority (CLA) has opened new headquarters in Kingston, Jamaica.

• IM Cannabis director Alon Dayan has resigned from the company’s board of directors.
• Ghanaian campaign highlights growing debate around cannabis policy and economic opportunities.